Last updated on February 2018

Open-Label Extension of RPC1063 as Therapy for Moderate to Severe Ulcerative Colitis


Brief description of study

The purpose of the trial is to determine the safety and efficacy of RPC1063 in patients diagnosed with moderate to severe ulcerative colitis.

Detailed Study Description

The trial is an open label extension study. Eligible patients from the RPC01-3101 trial diagnosed with moderate to severe ulcerative colitis will be enrolled to receive study medication for up to 5 years or until marketed approval.

Clinical Study Identifier: NCT02531126

Contact Investigators or Research Sites near you

Start Over

Receptos True North Study

Emmed Research
Pretoria, South Africa
1.0miles
  Connect »